TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27098455

Group type: EXPERIMENTAL
Intervention: Supervised weekly exercise from the 20th week of pregnancy onwards
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Supervised weekly exercise
Number of subjects: 81
Study: 25714880

Group type: EXPERIMENTAL
Intervention: High-dose rocuronium (1.2 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional-dose rocuronium (0.6 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (C and H)
Number of subjects: 50
Study: 24091981

Group type: EXPERIMENTAL
Intervention: Doxorubicin (Dox) and ifosfamide (Ifo) followed by high dose chemotherapy with ifosfamide, carboplatin, etoposide (HD-ICE) plus peripheral blood stem cell transplantation (PBSCT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with ifosfamide, carboplatin, etoposide (HD-ICE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus consolidation HD-ICE
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional dose chemotherapy plus external beam radiation therapy (EBRT)
Number of subjects: 30
Study: 22123184

Group type: EXPERIMENTAL
Intervention: 6β-naltrexol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19620427

Group type: EXPERIMENTAL
Intervention: 0.1% barium sulfate oral suspension (1,350 mL over 60-75 minutes)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 0.1% barium sulfate oral suspension
Number of subjects: 85

Group type: COMPARATOR
Intervention: No oral contrast material
Number of subjects: 85
Study: 16856570

Group type: EXPERIMENTAL
Intervention: Tc-99m MIBI SPECT
Number of subjects: 40
Study: 12935792

Group type: EXPERIMENTAL
Intervention: Tolperisone hydrochloride (150 mg) three times daily for 8 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10714424

Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg as dry powder, 2 x 5 mg blisters via Diskhaler, twice daily on day 1 and four times daily from day 2 to day 14)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8815686

Group type: EXPERIMENTAL
Intervention: Interferon‐alpha therapy
Number of subjects: 300000000

Group type: EXPERIMENTAL
Intervention: Nucleoside analogues
Number of subjects: 300000000

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccines and combination therapies
Number of subjects: 300000000
Study: 1382256

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) 10 mg/day orally at 7.00 p.m.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 63
Study: 3910548

Group type: EXPERIMENTAL
Intervention: Econazole (2 X 150 mg pessaries)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isoconazole (2 X 300 mg pessaries)
Number of subjects: 100
Study: 31671137

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29285709

Group type: EXPERIMENTAL
Intervention: IWT + dried tofu intake (DTG, n = 16; 111 kcal, 9.6 g protein, 6.0 g fat, and 4.6 g carbohydrate)
Number of subjects: 32

Group type: COMPARATOR
Intervention: IWT + placebo intake (PLG, n = 16; 108 kcal, 0.2 g protein, 5.5 g fat, and 14.4 g carbohydrate)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (DTG and PLG)
Number of subjects: 32
Study: 26797632

Group type: EXPERIMENTAL
Intervention: Isoflavone‐supplemented probiotic soy product (ISP)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Probiotic soy product (SP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Unfermented soy product (USP)
Number of subjects: 49
Study: 24952387

Group type: EXPERIMENTAL
Intervention: Text message assessments of sleepiness, fatigue, and concentration difficulties, with tailored intervention messages for those reporting high levels of sleepiness or fatigue.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving assessment only text messages.
Number of subjects: 0
Study: 22900547

Group type: EXPERIMENTAL
Intervention: Topical 0.05% cyclosporine A (CsA) eye drops for an average duration of 5.1 ± 3.5 months (1 ‐ 13 months)
Number of subjects: 16
Study: 20925493

Group type: EXPERIMENTAL
Intervention: Pumping stroke
Number of subjects: 10

Group type: COMPARATOR
Intervention: Circular stroke
Number of subjects: 10
Study: 17982924

Group type: EXPERIMENTAL
Intervention: Open food challenge
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 9
Study: 16113520

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 11952443

Group type: EXPERIMENTAL
Intervention: Video with realistic information about the upcoming perioperative procedure (group 1)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Video without surgery-related information (group 2)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Group 1 (video with realistic information)
Number of subjects: 101
Study: 9863864

Group type: EXPERIMENTAL
Intervention: IL-2 (9 Mio IU/d) every 6 weeks (Group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IL-2 (9 Mio IU/d) whenever CD4 cell count dropped below 1.25-fold of baseline (Group B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (HAART without IL-2)
Number of subjects: 64
Study: 8549944

Group type: EXPERIMENTAL
Intervention: azathioprine (2.5 mg/kg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study: 2225481

Group type: EXPERIMENTAL
Intervention: GHRH (1-29)NH2, 10 micrograms/kg/h
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: GHRH (1-29)NH2, 5 micrograms/kg/h
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 90964

Group type: EXPERIMENTAL
Intervention: Alprenolol (5-10 mg intravenously, followed by 200 mg twice a day orally)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 480
Study: 30935618

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Platelet pellet (PP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Induced blood clot (BC)
Number of subjects: 67
Study: 27637734

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg every 24 h for 48 h (standard dose group)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Intravenous pantoprazole 40 mg every 12 h for 48 h (double-dose group)
Number of subjects: 166
Study: 25435217

Group type: EXPERIMENTAL
Intervention: 125 μg ocriplasmin intravitreal injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 100
Study: 23295056

Group type: EXPERIMENTAL
Intervention: Adefovir-lamivudine combination
Number of subjects: 219

Group type: COMPARATOR
Intervention: Entecavir monotherapy
Number of subjects: 219
Study: 21103669

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 18786751

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d, followed by vitamin E 300 mg/d after 6 months, and homocysteine-lowering therapy (folic acid 5 mg/d, pyridoxine 100 mg/d, vitamin B12 1 mg/d) for another year.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 16635661

Group type: EXPERIMENTAL
Intervention: Q-switched alexandrite laser (QSAL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 32
Study: 15609890

Group type: EXPERIMENTAL
Intervention: Citronella repellent
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 9419397

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2.0 g daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8126258

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3611169

Group type: EXPERIMENTAL
Intervention: Biodegradable implants (polylactide-glycolide copolymer)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Metal AO plates and screws
Number of subjects: 56
Study: 30652982

Group type: EXPERIMENTAL
Intervention: Lumbosacral orthosis with routine physical therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Routine physical therapy alone
Number of subjects: 44
Study: 29024857

Group type: EXPERIMENTAL
Intervention: High-density negative air ions (30 or 60 min daily exposure)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zero-density negative air ions (placebo condition)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-density negative air ions
Number of subjects: 40
Study: 26910503

Group type: EXPERIMENTAL
Intervention: Dual treatment with rilpivirine plus boosted darunavir (DRV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Triple treatment (standard cART)
Number of subjects: 60
Study: 24745586

Group type: EXPERIMENTAL
Intervention: Epileptic students
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 22324319

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia without sedation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with sedation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 45
Study: 20127495

Group type: EXPERIMENTAL
Intervention: Micro-endoscopic discectomy (group 1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Micro discectomy (group 2)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Open discectomy (group 3)
Number of subjects: 240

Group type: COMPARATOR
Intervention: All groups (micro-endoscopic, micro, open)
Number of subjects: 240
Study: 17063156

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 16203281

Group type: EXPERIMENTAL
Intervention: Hybrid Capture 2 (HC2)
Number of subjects: 5026

Group type: COMPARATOR
Intervention: Polymerase Chain Reaction (PCR)
Number of subjects: 5026
Study: 12018757

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 893

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal system (NTS)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Combination of bupropion SR and NTS
Number of subjects: 893
Study: 10432175

Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues
Number of subjects: 0
Study: 8524716

Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Late intervention
Number of subjects: 39
Study: 2089297

Group type: EXPERIMENTAL
Intervention: 0.5 mg oestriol vaginal cream for 90 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Moisturizing cream
Number of subjects: 34
Study: 284065

Group type: COMPARATOR
Intervention: Dentifrice and mouthrinse containing fluorides (stannous fluoride and sodium fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dentifrice containing amine fluorides and placebo mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mouthrinse containing amine fluorides and placebo dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dentifrice containing stannous fluoride and placebo mouthrinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control group (placebo dentifrice and mouthrinse)
Number of subjects: 0
Study: 31757768

Group type: EXPERIMENTAL
Intervention: Whole-virome analysis
Number of subjects: 0
Study: 27885859

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training for 8 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 37
Study: 25012804

Group type: EXPERIMENTAL
Intervention: Laparoscopic magnetic sphincter augmentation (MSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 0
Study: 23652210

Group type: EXPERIMENTAL
Intervention: 3.7 GBq of iodine-¹³¹I
Number of subjects: 136

Group type: COMPARATOR
Intervention: 1.1 GBq of iodine-¹³¹I
Number of subjects: 136
Study: 22106979

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg / Pioglitazone 30 mg
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg / Pioglitazone 15 mg
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg / Pioglitazone 30 mg
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg / Pioglitazone 15 mg
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg / Pioglitazone 0 mg
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 0 mg / Pioglitazone 30 mg
Number of subjects: 377

Group type: COMPARATOR
Intervention: Candesartan cilexetil 0 mg / Pioglitazone 0 mg
Number of subjects: 377
Study: 19424032

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 17545701

Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine (sd-NVP) prophylaxis
Number of subjects: 740
Study: 15273929

Group type: EXPERIMENTAL
Intervention: Five different simple questioning techniques
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dichotomous questions regarding satisfaction
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rating using grades known from the German school system (1-6)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS; 0-100 mm)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: QoR-9 questionnaire
Number of subjects: 200
Study: 11212969

Group type: EXPERIMENTAL
Intervention: Cortisol 80 mg/day + L-arginine 21 g/day
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cortisol 80 mg/day + Placebo
Number of subjects: 3
Study: 9548602

Group type: EXPERIMENTAL
Intervention: TIM-ILP
Number of subjects: 832

Group type: COMPARATOR
Intervention: TM-ILP
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: M-ILP
Number of subjects: 832
Study: 7753427

Group type: EXPERIMENTAL
Intervention: Nicardipine (80-120 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nifedipine (40-60 mg daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 30
Study: 3058537

Group type: EXPERIMENTAL
Intervention: Dothiepin (75 mg orally at night)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30607817

Group type: EXPERIMENTAL
Intervention: Neratinib (Nerlynx®) for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neratinib (Nerlynx®)
Number of subjects: 0
Study: 28749729

Group type: COMPARATOR
Intervention: General message (same message as provided to all White participants)
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: 1 of 4 alternate messages framing the need for participation in terms of race and/or health disparities
Number of subjects: 1513

Group type: COMPARATOR
Intervention: General message
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Racial framing
Number of subjects: 1513
Study: 25584995

Group type: EXPERIMENTAL
Intervention: Single use hydrophilic coated catheter
Number of subjects: 66

Group type: COMPARATOR
Intervention: Multiple use polyvinylchloride catheter
Number of subjects: 66
Study: 23415937

Group type: EXPERIMENTAL
Intervention: Active tDCS (1 mA for 20 min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study: 21235615

Group type: EXPERIMENTAL
Intervention: Open healing (OH)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Submerged healing (SH)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both OH and SH
Number of subjects: 21
Study: 18854803

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14 (Dicoflor Elle, Dicofarm, Roma, Italy) administered orally, two tablets daily for 15 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antibiotic therapy followed by Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14
Number of subjects: 50
Study: 17194242

Group type: EXPERIMENTAL
Intervention: Aquatic Training (AT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 22
Study: 12599005

Group type: EXPERIMENTAL
Intervention: Neuroradiologists using CTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neuroradiologists using MRA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Other observers using CTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Other observers using MRA
Number of subjects: 60
Study: 10937511

Group type: EXPERIMENTAL
Intervention: Insulin glargine (30 microg/ml zinc)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Insulin glargine (80 microg/ml zinc)
Number of subjects: 256

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 256
Study: 8765253

Group type: EXPERIMENTAL
Intervention: Subcutaneous closed drainage system
Number of subjects: 197

Group type: COMPARATOR
Intervention: No subcutaneous closed drainage system
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Subcutaneous closed drainage system with prophylactic antibiotics
Number of subjects: 197

Group type: COMPARATOR
Intervention: No subcutaneous closed drainage system without prophylactic antibiotics
Number of subjects: 197
Study: 1576070

Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled via Turbohaler (TBH) at varying inspiratory flows (34 to 88 l min‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled via Turbohaler (TBH) with prior exhalation through the device
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled via Turbohaler (TBH) at approximately 34 l min‐1
Number of subjects: 10
Study: 6399986

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX)
Number of subjects: 0
Study: 30934155

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Men in upper age quartile (60.3‐67.6 years)
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Women in two highest age quartiles (54.6‐60.2 and 60.3‐67.6 years)
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 3881

Group type: COMPARATOR
Intervention: Men who smoked
Number of subjects: 3881

Group type: COMPARATOR
Intervention: Women who smoked
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Men and women sensitized to both grass and perennial allergens
Number of subjects: 3881
Study: 30420347

Group type: EXPERIMENTAL
Intervention: MYmind programme delivered by trained healthcare professionals
Number of subjects: 140

Group type: COMPARATOR
Intervention: CBT programme
Number of subjects: 140
Study: 27339736

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 prophylaxis (20-50 IU kg(‐1) two or three times per week for 12 months)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 prophylaxis (twice-weekly vs. three times-weekly dosing)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 during major surgeries
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 prophylaxis
Number of subjects: 62
Study: 25048508

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tramadol 100 mg in 500 mL 0.9%NaCl one hour before the procedure
Number of subjects: 74

Group type: COMPARATOR
Intervention: 500 mL 0.9%NaCl (control group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Postoperative analgesia (diclofenac 75 mg i.m.) when required
Number of subjects: 74
Study: 22158143

Group type: EXPERIMENTAL
Intervention: Vibration treatment at 25 Hz, 35 Hz, and 45 Hz with low amplitude (1 mm) and high amplitude (3.1 mm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Use of a soft pad during vibration treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vibration treatment (various frequencies and amplitudes)
Number of subjects: 20
Study: 21273805

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 18041883

Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg oral suspension 3 times/day for a maximum of 16 weeks
Number of subjects: 246
Study: 16195948

Group type: EXPERIMENTAL
Intervention: Universal classroom‐based intervention targeting disruptive behavior
Number of subjects: 664

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 664
Study: 12119249

Group type: EXPERIMENTAL
Intervention: Amiodarone plus irbesartan
Number of subjects: 154

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 154
Study: 11028251

Group type: EXPERIMENTAL
Intervention: Heparin i.v. bolus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot study of bolus dosing
Number of subjects: 0
Study: 8986182

Group type: EXPERIMENTAL
Intervention: Countercurrent heat exchangers (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study: 1446565

Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-stimulus control
Number of subjects: 60
Study: 6367690

Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Pre-DST HYPAC measures (morning plasma cortisol, urine free cortisol, CSF cortisol levels)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Age and body weight correlation
Number of subjects: 204
Study: 31677670

Group type: EXPERIMENTAL
Intervention: Herbst appliance with miniscrews
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard Herbst appliance without miniscrews
Number of subjects: 13
Study: 29376858

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET), 90 minutes of aerobic and strength training, 72 treatment sessions over 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cognitive Treatment (CT), 90 minutes of cognitive stimuli
Number of subjects: 34